1 / 2

The Use of Cost-Effectiveness Information in Coverage Policy Decisions in the U.S. and the U.K.

The Use of Cost-Effectiveness Information in Coverage Policy Decisions in the U.S. and the U.K. Stirling Bryan Ph.D. University of Birmingham, U.K. University of British Columbia, Canada. Britain Stirs Outcry by Weighing Benefits of Drugs Versus Price.

morela
Télécharger la présentation

The Use of Cost-Effectiveness Information in Coverage Policy Decisions in the U.S. and the U.K.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Use of Cost-Effectiveness Information in Coverage Policy Decisions in the U.S. and the U.K. Stirling Bryan Ph.D. University of Birmingham, U.K. University of British Columbia, Canada

  2. Britain Stirs Outcry by Weighing Benefits of Drugs Versus Price Millions of patients around the world have taken drugs introduced over the past decade to delay the worsening of Alzheimer's disease. … But this year, an arm of Britain's government health-care system, relying on some economists' number-crunching, said the benefit isn't worth the cost. It issued a preliminary ruling calling on doctors to stop prescribing the drugs. THE WALL STREET JOURNAL November 22, 2005; Page A1

More Related